48 results
8-K
EX-99.1
FATE
Fate Therapeutics Inc
4 Aug 21
Fate Therapeutics Appoints Yuan Xu to its Board of Directors
9:20am
development unit focusing on innovative medicines such as engineered cell therapies, gene therapies, and antibody drug conjugates. Dr. Xu currently serves … with the Company’s board and management team as we move into late-stage clinical development, scale manufacture, and seek to make these innovative cancer
8-K
EX-99.1
FATE
Fate Therapeutics Inc
17 Mar 14
Fate Therapeutics Appoints Dr. Robert S. Epstein to its Board of Directors
12:00am
and health economics, and his proven leadership in advancing highly innovative, paradigm-changing technologies to improve patient care
8-K
FATE
Fate Therapeutics Inc
18 May 18
Fate Therapeutics and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to include Gene-edited T-cell Immunotherapies
4:05pm
CAR T cells, including the use of CRISPR and other innovative technologies for their production, in each case to research, develop, and commercialize
8-K
EX-99.1
FATE
Fate Therapeutics Inc
5 May 20
Fate Therapeutics Announces Changes to its Board of Directors
4:03pm
with tremendous experience in the development of innovative cell-based cancer immunotherapies and collaborations that maximize strategic value, and we are excited
8-K
FATE
Fate Therapeutics Inc
4 Aug 21
Fate Therapeutics Appoints Yuan Xu to its Board of Directors
9:20am
from 2008 to 2014, where she led several functions in the U.S. and Europe including the biotherapeutics development unit focusing on innovative
8-K
EX-99.1
logz7uwrw
17 Jul 19
Fate Therapeutics Announces the Appointment of Dr. Shefali Agarwal to its Board of Directors
4:03pm
8-K
EX-99.1
oc2xzc5yy k2wp
30 Jun 22
ONO to Contribute Novel Binding Domains for a Second Solid Tumor Antigen to the Collaboration
4:06pm
8-K
EX-99.1
irywlgtv7h
18 May 18
Fate Therapeutics and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to include Gene-edited T-cell Immunotherapies
4:05pm
8-K
EX-99.1
l09a17v0
8 Aug 23
Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
4:07pm
8-K
EX-99.1
9hc rw7190
6 Aug 18
Fate Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Operational Progress
4:10pm
8-K
EX-99.1
m5ksdr2m6gr3d
3 May 23
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates
4:06pm
8-K
EX-99.1
ssezhos0wiv3euzg
11 May 20
Fate Therapeutics Reports First Quarter 2020 Financial Results and Highlights Operational Progress
4:01pm
8-K
EX-99.1
l9t6m v1r
17 Nov 14
Results of Operations and Financial Condition
12:00am
S-3
kmlwpml7m kiwr0dh
1 Oct 14
Shelf registration
12:00am